For example, α-thalassemia is present in about 50% of patients tested, potentially interfering with strategies to use Hb level as a marker of iron status and lessening justifications for iron supplementation as an anemia control measure.14,41,42. This evidence concerns the gene GSTM1 and thalassemia.